Navigation Links
FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis

Food and Drug Association as approved the drug CLARINEX-D 12 HOUR for use in treating symptoms of seasonal allergic rhinitis. // CLARINEX-D 12 HOUR is a drug containing a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg. FDA has approved the drug for use in persons above 12 years of age. The drug has been found effective in curing persons with nasal and non-nasal symptoms occurring due to seasonal allergic rhinitis. Two clinical studies in 1,248 patients have found that the drug CLARINEX-D is found to be more effective in controlling allergic symptoms than the drug psueoephedrine alone.

The drug contains a delivery system, which delivers psudoephedrine in a consistent manner, and a dosage of two times a day of the nasal drug is found to be effective in controlling symptoms of allergic rhinitis and relieves nasal blockage and congestion, running nose, sneezing, watery eyes and itchy throat. The drug is found to be very effective in controlling allergic symptoms but has been found to be associated with mild side effects of insomnia, headache, pharyngitis, weakness and fatigue.


'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves drug for rare liver disease
4. FDA approves first pocket-sized EKG machine
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
7. Madras High Court Disapproves of Comparative Advertisements
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Old flu drugs not effective against seasonal influenza
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental health ... health systems reform legislation in more than fifty years. We applaud the bipartisan ... our elected officials to improving mental health services and supports in our nation. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader that ... a new partnership with Splashtop Inc. This remote control for Android extends Wavelink’s ... businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility management ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... acquired Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 ... other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
(Date:12/8/2016)... December 8, 2016 According to the ... Pens Market is expected to be worth US$9.7 bn ... in 2015. Between the forecast years of 2016 and 2024, ... of 7.9%. The leading players operating in the global diabetes ... Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market ...
Breaking Medicine Technology: